Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

Nature business

Key Points:

  • Obesity is a multifaceted, chronic disease driven by metabolic dysfunction that can contribute to the development and progression of MASLD1,2,3,4,5. MASLD is defined by hepatic steatosis identified by

Trending Business

Trending Technology

Trending Health